H1N1 Swine Flu Virus Patented by Medimmune Back in 2008

Medimmune Patented H1N1 Swine Flu Virus Back in 2008

September 11, 2009

fightbackh1n1.com - According to Dr. T Ott, the Swine Flu patent is owned by none other than Medimmune who stands to profit around $151 million dollars from US taxpayers.

MedImmun, LLC, headquartered in Gaithersburg, Maryland, became a wholly owned subsidiary of AstraZeneca in 2007. Since being acquired, MedImmune has remained a Maryland-based biotechnology development enterprise.

It produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for $1.06 billion of its $1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004.

FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market -- the millions of young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store

According to MedImmune website they are making a signficant, rapid response with a vaccine to the H1N1 variant of influenza, known as Swine flu. In early June 2009 it won a Department of Health and Human Services (HHS) contract, worth $90m.

Under the contract with HHS, MedImmune will continue to make its seasonal FluMist vaccine, and it also will develop a vaccine targeted specifically at the H1N1 virus. MedImmune then won a second contract to test its nasal spray flu technology as a viable treatment for the H1N1.

And now according to Dr T Ott investigation Medimmune applied for and received the patient for Swine Flu Virus back in 2008.

But according to WHO, "OFFICIALLY" H1N1 is created naturally, and it's a new strain of influenza virus first identified in April 2009. If so how could Medimmune get the patent for the same back in 2008 ?

In past we reported about how Baxter Files H1N1 Swine Flu Vaccine Patent a Year Ahead of Outbreak.


According to Dr. Ott Medimmune Patent it is not for a vaccine, it is for the creation of the specific strain as well as a set of substrains and any splice of cells in the same regions.

Down below is Medimmune Patent Document please read Page 36 - Paragraph - 33 and last page of patent.
Medimmune H1N1 Swine Flu Virus - PATENT - 2008

Update:

The following link is the most important. It shows that the original application was filed on August 28, 2007.

Start off from here http://portal.uspto.gov/external/portal/pair and when you get to the search page make sure "application number" is checked off and in the search field put in the application number of: 60/966,724

When it opens the page click on the tab "Image File Wrapper" then select "Specifications" and go to page "13" of the specifications. Here you will see the virus references to the viruses as noted above, and it did so on "08/28/07" long before the virus was promoted as a "New and Deadly Strain" morphed out of a pig farm in Mexico.

We emailed the above Patent document to expert, and very soon publishing the brief summery about the same.